Rechercher des projets européens

32 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

"Proposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes" (EXALT)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

"Type-1 diabetes (T1D) is an autoimmune disease in which pancreatic β-cells are gradually destroyed by autoreactive T-cells recognising autoantigens (Auto-Ag) such as GAD65 and insulin. ImCyse, a small SME, has developed a new technology based on short synthetic peptides flanked with a thioredox motif, which silence the pathogenic immune response against several auto-Ag through activation of one a ...
Voir le projet

 7

 TERMINÉ 

Biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2018,

In renal allograft recipients, 10-year graft survival has not improved over the past decades. Histological examination of graft biopsies has long been the gold standard to confirm graft injuries, but biopsies are invasive and histological grading is not very robust. There is thus a need for robust, non-invasive methods to predict and diagnose acute and chronic graft lesions, to improve patient tre ...
Voir le projet

 13

 TERMINÉ 

Nanotherapeutics for antibiotic resistant emerging bacterial pathogens (NAREB)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2018,

Increase in antibiotic resistance is a global concern worldwide. The project NAREB's main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the therapy of multi-drug resistant (MDR) tuberculosis (TB) and MRSA infections in European MDR patients.NAREB will address the problem of drug bioavailability inside the infected macrophages, transport ...
Voir le projet

 16

 TERMINÉ 

Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT)

Date du début: 1 mars 2011, Date de fin: 31 déc. 2017,

RDEB is one of the most severe rare genetic skin diseases of children and adults characterized by skin blistering resulting from lack of expression of type VII collagen. There is no treatment for this life-threatening disease. In March 2009, we obtained the orphan drug designation for the Medicinal product: “Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vecto ...
Voir le projet

 10

 TERMINÉ 

Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease (Repair-HD)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

This project will tackle the huge complexity of taking stem cell therapies to clinical application for neurodegenerative disease by focusing on selective differentiation of a single neuronal phenotype (medium spiny striatal neuron: MSN) for a single well-defined disease (Huntington’s: HD). Our consortium contains expertise in all elements required to drive this technology to the point of clinical ...
Voir le projet

 10

 TERMINÉ 

Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

The Fibro-Targets project is a multi-disciplinary 4 years program involving 10 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure. The project is based on the hypothesis that the intervention on novel fibrosis-related targets involved in the p ...
Voir le projet

 11

 TERMINÉ 

Anti-Parasitic Drug Discovery in Epigenetics (A-PARADDISE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2017,

This proposal builds on the proven methodology developed in the SEtTReND FP7 project to develop inhibitors of schistosome HME as lead compounds for new drugs. We will employ a target-based strategy for the development of novel drug leads against schistosomiasis, leishmaniasis, Chagas disease and malaria by targeting histone modifying enzymes (HME), in particular those involved in acetylation/deace ...
Voir le projet

 16

 TERMINÉ 

European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke (EuroHYP-1)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet

 38

 TERMINÉ 

SYSTEMS BIOLOGY OF PATHWAYS INVOLVING BRAIN AGEING (AGEDBRAINSYSBIO)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

In spite of valuable approaches applied to get a broad understanding of genetic, epidemiologic and molecular and system-level biological principles of human aging, cognitive decline remains as one of the greatest health challenges of the old age, with nearly 50% of adults over 85 afflicted of Alzheimer’s disease. Furthermore, drug development has not performed as expected in clinical trials, at le ...
Voir le projet

 15

 TERMINÉ 

Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases (PreDicta)

Date du début: 1 oct. 2010, Date de fin: 31 mars 2016,

Chronic inflammatory diseases associated with allergy, including asthma and rhinitis, constitute a major and continuously growing public health concern for Europe. However, the causative factors and mechanisms converting a physiological inflammatory reaction to a chronic response triggering allergic disease remain elusive.Viral infections, particularly those caused by human rhinoviruses (RV) are t ...
Voir le projet

 13

 TERMINÉ 

Stem Cells for Relevant Efficient Extended and Normalized Toxicology (SCR&TOX)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely ...
Voir le projet

 16

 TERMINÉ 

Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonates (TINN2)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

"The aim of TINN2 is to evaluate azithromycin, included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. Azithromycin is a macrolid antibiotic with anti-inflammatory properties active against Ureaplasma. It might be effective in reducing the severity of bronhopulmonary disease in which Ureaplasma infection and inflammation play a r ...
Voir le projet

 17

 TERMINÉ 

HEPATIC MICROFLUIDIC BIOREACTOR (HEMIBIO)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

The goal of HeMiBio is to develop a hepatic microfluidic bioreactor from human iPSC-derived hepatocytes, hepatic sinusoidal endothelial cells (HSEC) and stellate cells (HSC), suitable for inclusion in a repeated dose toxicity testing strategy of pharmaceuticals/cosmetic ingredients. The successful creation of such a liver-device requires (a) homotypic and heterotypic interactions between the three ...
Voir le projet

 13

 TERMINÉ 

Evaluation of antibiotics (ciprofloxacin and fluconazole) for the treatment of infections in preterm and term neonates (TINN)

Date du début: 1 nov. 2008, Date de fin: 31 oct. 2015,

The aim of TINN is to evaluate ciprofloxacin, fluconazole and micafungin in neonates; two anti-infectious drugs included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. These drugs are prescribed off-label to treat neonatal infections that are life threatening situations and associated with long-term complications. In order to val ...
Voir le projet

 16

 TERMINÉ 

Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance (OVER-MYR)

Date du début: 1 janv. 2012, Date de fin: 30 juin 2015,

Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patient’s survival.Currently-used drugs target both MM cells (MMC) and c ...
Voir le projet

 11

 TERMINÉ 

Mechanisms of the Development of ALLergy (MEDALL)

Date du début: 1 déc. 2010, Date de fin: 31 mai 2015,

Causes explaining the epidemic of IgE-associated (allergic) diseases are unclear. MeDALL (Mechanisms of the Development of Allergy) aims at generating novel knowledge on mechanisms of allergy initiation, in particular in childhood. To understand how a complex network of genetic and environmental factors leads to complex allergic phenotypes, a novel stepwise, large and integrative translational app ...
Voir le projet

 24

 TERMINÉ 

The role of intestinal microflora in non-alcoholic fatty liver disease (NAFLD) (FLORINASH)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2014,

As worldwide metabolic disease pandemics rise relentlessly with their concomitant clinical complications such as non alcoholic fatty liver disease, FLORINASH proposes an innovative research concept to address the role of intestinal microfloral activity in the pathogenesis of NAFLD. Firstly, to discover novel metabolic markers for the differential diagnosis and prediction of patient risk. Secondly, ...
Voir le projet

 6

 TERMINÉ 

Innovative strategies to generate human hepatocytes for treatment of metabolic Liver diseases: Tools for personalized cell therapy (InnovaLiv)

Date du début: 1 déc. 2011, Date de fin: 30 nov. 2014,

Transplantation of donor hepatocytes has become an alternative to liver transplantation for the treatment of liver diseases. However, in addition to the complication imposed by severe shortage of donor livers, adult hepatocytes cannot be expanded in vitro. Autologous transplantation of genetically corrected hepatocytes represents another strategy as it circumvents the need for immunosuppression bu ...
Voir le projet

 7

 TERMINÉ 

Health Competence in Europe (HEALTHCOMPETENCE)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2014,

The results generated through EC funded projects represent a considerable part of health research in Europe. Access to high-quality information on these research activities & results is therefore critical for planning & strategic decision making, and hence strengthening the involved stakeholders' innovation capabilities. The objective of HealthCompetence is to ensure an adequate access to this inf ...
Voir le projet

 4

 TERMINÉ 

Highlighting EU-funded Health research results via TV media and the internet (HIGHLIGHT)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2014,

"The strategic objective of HIGHLIGHT is to contribute to the development of public awareness on European Health research in all European countries through the professional use of television media and the internet.The technical objectives of HIGHLIGHT are:• Surf the Health Theme in FP7 to identify most prominent results achieved by individual projects in FP7.• Produce and release a series of 21 hi ...
Voir le projet

 7

 TERMINÉ 

Coordination Action in support of the implementation of a Joint Programming Initiative for Combating Neurodegenerative Diseases, in particular Alzheimer’s disease (JUMPAHEAD)

Date du début: 1 sept. 2010, Date de fin: 31 août 2014,

The objective of the Coordination Action JUMPAHEAD is to support the implementation of the pilot Joint Programming Initiative on combating neurodegenerative diseases, in particular Alzheimer’s disease (JPND).Neurodegenerative disorders are incurable and debilitating conditions that result in progressive degeneration or death of nerve cells. Of these, the dementias are responsible for the greatest ...
Voir le projet

 13

 TERMINÉ 

"Myasthenias, a group of immune mediated neurological diseases: from etiology to therapy." (FIGHT-MG)

Date du début: 1 déc. 2009, Date de fin: 31 mai 2014,

"Myasthenia Gravis (MG) is a heterogeneous rare autoimmune neurological disease affecting the neuromuscular junction (NMJ). The molecular events causing and maintaining MG are still unknown and current treatments do not lead to remission and entail considerable side-effects stressing the need for improved therapies. We will address the: 1. Natural course of disease: determine factors associated wi ...
Voir le projet

 13

 TERMINÉ 

Understanding and combating human age-related muscle weakness (MYOAGE)

Date du début: 1 janv. 2009, Date de fin: 30 juin 2013,

Ageing of skeletal muscle results in a progressive loss of mobility that decreases the quality of life and has major economic and social consequences for society at large. Increasing muscle weakness is a major component of muscle ageing. In the elderly muscles become atrophic (loss in muscle mass) and weaker (loss in muscle force), more susceptible to damage and consequently regenerate and recover ...
Voir le projet

 18

 TERMINÉ 

NONHUMAN ADENOVIRUS VECTORS FOR GENE TRANSFER TO THE BRAIN (BrainCAV)

Date du début: 1 oct. 2008, Date de fin: 31 mars 2013,

Formidable challenges remain to prevent and treat successfully neurodegenerative diseases. Traditional pharmacological approaches, as well as those using stem cells, have made progress but their impact remain limited. As suggested by clinical results in Canavan and Parkinson’s disease, gene transfer offers substantial potential. However, this strategy of therapeutic intervention also brings unique ...
Voir le projet

 12

 TERMINÉ 

Schistosoma Epigenetics - Targets, Regulation, New Drugs (SEtTReND)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2012,

We propose to develop novel drug leads for the therapy of the major human parasitic disease, schistosomiasis, using a holistic approach that will enable us to progress from the cloned target protein to the lead compound and from epigenetic inhibitors to crucial targets. For this, we have chosen to target the histone modifying enzymes (HME); histone deacetylases (HDAC), histone acetyltransferases ( ...
Voir le projet

 9

 TERMINÉ 

Development of culture conditions for the differentiation of hES cells into hepatocytes (LIV-ES)

Date du début: 1 oct. 2008, Date de fin: 31 mars 2012,

"The liver is associated with many types of diseases which can only be treated by Orthotopic liver transplants. However, shortage of organ donors represents a major limitation for wide-application of this therapy. Additionally, expansion of fully-functional hepatocytes in vitro remains an important challenge for the drug discovery industry. Human Embryonic Stem cells (hESCs) offer a promising new ...
Voir le projet

 7

 TERMINÉ 

NASAL VACCINATION AGAINST RESPIRATORY INFECTIONS IN YOUNG CHILDREN (CHILD-INNOVAC)

Date du début: 1 mars 2008, Date de fin: 29 févr. 2012,

"Respiratory infections are the most frequent cause of childhood morbidity and mortality worldwide. For many respiratory pathogens no vaccine is available, for others classical immunisations remain insufficiently effective. This project concerns the development of novel, nasal vaccines against two major respiratory pathogens, B. pertussis and Respiratory Syncytial Virus (RSV). No vaccine is yet av ...
Voir le projet

 10

 TERMINÉ 

Circuit specific approaches to retinal diseases (RETICIRC)

Date du début: 1 janv. 2009, Date de fin: 31 déc. 2011,

"The RETICIR project focuses on neuronal mechanisms of vision from photoreceptor level to visual cortex. Physiological knowledge of the visual system will be used to address pathophysiological neuronal mechanisms of diseases affecting vision. In the project we will identify molecular and cellular disease mechanism of retinitis pigmentosa and glaucoma, and will demonstrate restoration of vision in ...
Voir le projet

 6

 TERMINÉ 

Innovative contrast imaging by non-linear optics (NLO) for the observation of biological tissues in vivo and in real time, at cellular and molecular levels (CARS Explorer)

Date du début: 1 mars 2008, Date de fin: 31 août 2011,

The CARS EXPLORER seeks to demonstrate the concept of innovative light-based contrasting technologies for functional in situ imaging in life science and biomedical research. Our ultimate goal is to develop an endoscope based on non-linear optics (NLO) and laser pulse phase shaping. Non linear laser pulse interactions with living tissues provide unique possibilities, such as an absence of sample pr ...
Voir le projet

 7

 TERMINÉ 

Targeting assembly of infectious HIV particles (HIV ACE)

Date du début: 1 mars 2008, Date de fin: 31 août 2011,

"AIDS remains one of the major life threatening infectious diseases in the world today. A constant supply of novel antiretrovirals (ARVs) is needed to respond to the limitations of current drugs. By the end of 2007, the therapeutic arsenal against HIV is expected to comprise ARVs blocking all major steps of HIV replication, except for particle assembly and budding. Members of HIV-ACE were instrume ...
Voir le projet

 8

 TERMINÉ 

Targeting alpha-particle emitting radionuclides to combat cancer (TARCC)

Date du début: 1 janv. 2008, Date de fin: 30 juin 2011,

"This project aims at improving drug delivery to cancer cells by developing targeted radiotherapy with alpha-emitting radionuclides. Alpha particles emitted by radionuclides have short tracks (about 100 microns) in body tissues. As a result, they should be most appropriate to treat small-size tumours and isolated cancer cells. This project proposes the development of improved vectors and targeting ...
Voir le projet

 11

 TERMINÉ 

Mycobacterium tuberculosis W-Beijing genetic diversity and differential virulence and host immune responses (TB-VIR)

Date du début: 1 avr. 2008, Date de fin: 31 mars 2011,

"Improvements in TB control require the development of new tools for rapid and accurate diagnosis and intervention. This development is likely to benefit from more detailed knowledge of microbe-host relationships during infection. Following M. tuberculosis infection, only 5-10% of immunocompetent individuals develop TB. It is increasingly thought that the virulence of the infecting strain, togethe ...
Voir le projet

 11